Phase 2 Study Of IDH 1/2 Inhibitor Vorasidenib In Patients With IDH2-Mutated Intrahepatic Cholangiocarcinoma

November 10, 2026 updated by: M.D. Anderson Cancer Center

To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

Primary Objectives and Endpoints To evaluate the safety and efficacy of vorasidenib in participants with IDH2-mutated iCCA.

Primary endpoints for the study will be the evaluation of dose-limiting toxicities (DLTs) and landmark progression-free survival (PFS).

Study Type

Interventional

Enrollment (Estimated)

26

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Texas
      • Houston, Texas, United States, 77030
        • UT MD Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • Milind Javle, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Eligibility Criteria

  1. Patients with diagnosis of unresectable or metastatic iCCA (confirmed by treating clinician) who have received at least one first-line standard of care systemic therapy for iCCA.

  2. Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer

  3. Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS).

  4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.

  5. Age ≥18 years.

  6. ECOG performance status ≤2 (Karnofsky ≥60%,).

  7. Patients must have adequate organ and marrow function as defined below:

    • absolute neutrophil count ≥1,000/mcL
    • platelets ≥75,000/mcL
    • total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
    • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional ULN
    • Creatinine ≤ institutional ULN
  8. For Participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable

  9. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For Participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.

  10. Participants with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

  11. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, Participants should be class 2B or better.

  12. The effects of vorasidenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

    • Postmenopausal (no menses in greater than or equal to 12 consecutive months).
    • History of hysterectomy or bilateral salpingo-oophorectomy.
    • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
    • History of bilateral tubal ligation or another surgical sterilization procedure.
  13. Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

  14. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and not donate sperm for the duration of study participation, and 4 months after completion of vorasidenib administration.

  15. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  1. Prior treatment with an IDH inhibitor.

  2. Participants who have had chemotherapy or radiotherapy within 3 weeks prior to entering the study.

  3. Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 2 with the exception of alopecia.

  4. Participants who are receiving any other investigational agents.

  5. Concomitant use of strong CYP3A4 inducers or inhibitors, or medications with potential for significant drug-drug interactions with vorasidenib as detailed in the prescribing information (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf).

  6. Participants with active brain metastases. The investigator(s) must state a medical or scientific reason if Participants who have brain metastases will be excluded from the study.

  7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to [list out Agent(s)] or other agents used in study.

  8. Examples of such agents or substances include those that interact through the CYP450 isoenzyme system or other sources of drug interactions (e.g., P-glycoprotein). Specifically excluded substances may be listed below and presented as an appendix. If appropriate, the following text concerning CYP450 interactions may be used or modified.

    Note: This must account for all agents to be used in this study, including commercial agents. Please refer to the FDA product labels for all commercial agents and include information on prohibited concomitant medications in all applicable sections of the protocol.

  9. Participants with uncontrolled intercurrent illness (Indicate clearly what type or extent)

  10. Human immunodeficiency virus (HIV)-infected Participants are excluded, except those on effective ART with undetectable viral load, who are eligible.

  11. Participants with psychiatric illness/social situations that would limit compliance with study requirements.

  12. Pregnant women are excluded from this study because vorasidenib is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorasidenib, breastfeeding should be discontinued if the mother is treated with vorasidenib. These potential risks may also apply to other agents used in this study.

  13. The investigator(s) must state a medical or scientific reason if Participants who are cancer survivors will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Safety Run-In/Expansion

Treatment with Vorasidenib (PO) Q4W

Give by po

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and adverse events (AEs
Time Frame: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

Through study completion; an average of 1 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Milind Javle, MD, UT MD Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 29, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2031

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2026-1152
  • NCI-2026-08423 (Other Identifier: NCI-CTRP Clinical Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe